-
1.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 审中-公开结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途
公开(公告)号：WO2008118356A3
公开(公告)日：2008-11-20
申请号：PCT/US2008003735
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA , BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。
-
公开(公告)号：ZA200907385B
公开(公告)日：2011-04-28
申请号：ZA200907385
申请日：2009-10-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： TYSON KERRY LOUISE , SHOCK ANTHONY , BROWN DEREK THOMAS , TAYLOR FREDERICK R , SU LIHE , HSU YEN-MING , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , ADAMS RALPH , POPPLEWELL ANDREW GEORGE , BURKLY LINDA C , ROBINSON MARTYN KIM
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：AU2008232409A1
公开(公告)日：2008-10-02
申请号：AU2008232409
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： GARBER ELLEN A , ROBINSON MARTYN KIM , SHOCK ANTHONY , TAYLOR FREDERICK R , BURKLY LINDA C , HSU YEN-MING , FERRANT-ORGETTAS JANINE L , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , SU LIHE , ADAMS RALPH , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：CA2681530C
公开(公告)日：2017-03-28
申请号：CA2681530
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C12N15/13 , A61K39/395 , C07K16/28 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody.
-
公开(公告)号：BRPI0809042A2
公开(公告)日：2014-09-16
申请号：BRPI0809042
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
Patent Agency Ranking
公开(公告)号：EA019636B1
公开(公告)日：2014-05-30
申请号：EA200970879
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Изобретениеотноситсяк связывающимбелкам, включающимантитела, производныеантители фрагментыантител, которыеспецифическисвязываютсяс белком CD154 (CD40L). Такжеданноеизобретениеотноситсяк химерному, гуманизированномуилиполностьючеловеческомуантителу, производномуантителаи фрагментуантитела, которыеспецифическисвязываютсяс эпитопом, скоторымспецифическисвязываетсягуманизированныйфрагмент Fab, содержащийпоследовательностьвариабельнойобластитяжелойцепи SEQ ID NO: 1 исодержащийпоследовательностьвариабельнойобластилегкойцепи SEQ ID NO: 2. CD154-связывающиебелкиподанномуизобретениюмогутпроявлятьпониженнуюэффекторнуюфункциюпосравнениюсовторыманти-CD154-антителом. CD154-связывающиебелкиподанномуизобретениюмогутбытьпригоднымидлядиагностическихи терапевтическихспособов, напримерприлечениии профилактикезаболеваний, втомчислетаковых, которыевключаютнежелательныеиммунныереакции, опосредуемыевзаимодействиями CD154-CD40.
-
公开(公告)号：SG196697A1
公开(公告)日：2014-02-13
申请号：SG2012055786
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: - 126 - Abstract BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODYDERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 ANDUSES THEREOF This invention provides binding proteins, includingantibodies, antibody derivatives and antibody fragments, thatspecifically bind a CD 154 (CD4OL) protein. This invention alsoprovides a chimeric, humanized or fully human antibody, antibodyderivative or antibody fragment that specifically binds to an epitopeto which a humanized Fab fragment comprising a variable heavy chainsequence according to SEQ ID NO: 1 and comprising a variable lightchain sequence according to SEQ ID NO: 2 specifically binds. CD154binding proteins of this invention may elicit reduced effectorfunction relative to a second anti-CD154 antibody. CD154 bindingproteins of this invention are useful in diagnostic and therapeuticmethods, such as in the treatment and prevention of diseasesincluding those that involve undesirable immune responses that aremediated by CD154-CD40 interactions. Fig. 19
-
公开(公告)号：NZ580245A
公开(公告)日：2012-01-12
申请号：NZ58024508
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: An anti-CD154 antibody that comprises the heavy chain CDR1, CDR2 and CDR3 sequence SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively and the light chain CDR1, CDR2 and CDR3 sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 respectively. Also disclosed are methods of the production of the antibody and uses thereof for treating rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma and multiple sclerosis.
-
公开(公告)号：ECSP099683A
公开(公告)日：2009-12-28
申请号：ECSP099683
申请日：2009-10-08
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： POPPLEWELL ANDREW GEORGE , BROWN DEREK THOMAS , ADAMS RALPH , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: Esta invención proporciona proteínas de unión, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que específicamente se unen a la proteína CD154 (CD40L). Esta invención también proporciona un anticuerpo quimérico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que específicamente se une a un epítopo al cual se une un fragmento Fab humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteínas de unión CD154 de esta invención pueden producir una función efectora reducida con relación a un segundo anticuerpo anti-CD154. Las proteínas de unión CD154 de la invención son útiles en métodos de diagnóstico y terapéuticos, tales como en el tratamiento y prevención de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que están mediadas por las interacciones de CD154-CD40
-
公开(公告)号：AU2013203712A1
公开(公告)日：2013-05-02
申请号：AU2013203712
申请日：2013-04-11
Applicant: BIOGEN MA INC , UCB PHARMA SA
Inventor： BURKLY LINDA , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE , TAYLOR FREDERICK R , HSU YEN-MING , SU LIHE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Abstract This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions. FIGURE 19: inhibition of IgG Immune Response to Tetanus Toxoid in Cynomolgus Monkeys Primary Immune Response to TT -
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.021 seconds)
